ArriVent BioPharma, Inc.
For the period ended Oct 25, 2026. Filed Oct 26, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 25, 2026 · Filed Oct 26, 2026
Use the contents to explore the available documents and sections.
AVBP$13.64+11.5%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Dose Optimization and Next Steps
Dose Optimization and Next Steps
ARR-217 has advanced into Phase 1b dose optimization at doses of 5 and 6 mg/kg Q3W with further dose optimization data expected in 2027.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.